Depression and Anxiety in Adults With Hidradenitis Suppurativa
Authors: Myrela O. Machado, Vicky Stergiopoulos, Michael Maes, Paul A. Kurdyak, Pao-Yen Lin, Liang-Jen Wang, Yu-Chiau Shyu, Joseph Firth, Ai Koyanagi, Marco Solmi, Afsaneh Alavi, Vincent Piguet, Andre F. Carvalho
Journal: JAMA Dermatology (2019)

<h3>Importance</h3> Previous studies suggest that depression and anxiety are common in patients with hidradenitis suppurativa (HS), more so than other dermatological conditions. Yet, to the authors' knowledge, no previous systematic review or meta-analysis has estimated the prevalence or odds ratio (OR) for those psychiatric comorbidities in this population. <h3>Objective</h3> To assess the prevalence and odds for depression and anxiety in patients with HS. <h3>Data Sources</h3> From July 25 to September 30, 2018, observational studies investigating the prevalence and odds for depression and anxiety in adults with HS were systematically searched without language restriction from the inception of each database to July 25, 2018, in PubMed/MEDLINE, Embase, and PsycINFO databases. Searches used various configurations of the terms<i>hidradenitis suppurativa</i>;<i>acne inversa</i>;<i>depressive disorder</i>;<i>depression</i>;<i>anxiety</i>;<i>anxiety disorders</i>;<i>phobia</i>,<i>social</i>;<i>suicide</i>; and<i>suicide</i>,<i>attempted</i>. In addition, the reference lists of included references were screened manually. <h3>Study Selection</h3> Two investigators independently screened references that measured prevalence rates and odds for depressive and anxiety symptoms in patients with HS. Of 136 unique references, 10 ultimately met inclusion criteria. <h3>Data Extraction and Synthesis</h3> Relevant data were extracted from eligible references. Authors were contacted to provide further information when necessary. Methodological quality of included studies was assessed through a modified version of the Newcastle-Ottawa Scale. Random-effects models were used to synthesize available evidence. <h3>Main Outcomes and Measures</h3> Prevalence rates and ORs for depression and anxiety in adults with HS were the primary outcome measures. Heterogeneity across studies was assessed with the<i>I</i><sup>2</sup>statistic. Sources of heterogeneity were explored through subgroup and meta-regression analyses. <h3>Results</h3> Ten studies comprising 40 307 participants with HS met inclusion criteria. The overall prevalence of depression was 16.9% (95% CI, 9.9%-27.2%). Heterogeneity was large. In the subgroup of studies that considered a clinical criteria–based diagnosis of depression, the prevalence of depression was 11.9% (95% CI, 4.9%-26.2%), compared with 26.8% (95% CI, 20.4%-34.5%) in studies that used a screening instrument. The methodological quality of included studies moderated those findings. The OR for depression in individuals with HS compared with individuals without HS was 1.84 (95% CI, 1.57-2.15). The prevalence of anxiety was 4.9% (95% CI, 1.7%-13.2%); there were insufficient data to determine an odds ratio for anxiety in persons with HS because 2 studies included a comparison group. <h3>Conclusions and Relevance</h3> This systematic review and meta-analysis indicates that depression and anxiety are common comorbid conditions in patients with HS. Results suggest that the development of strategies to recognize and treat those psychiatric comorbidities in patients with HS is warranted.